Rob Davis, chairman and CEO, on our Q1 2024 #earnings : merck.us/3xTMjMR $MRK

#ByTheNumbers : Check out highlights from our Q1 2024 #earnings report. $MRK

Join us today at 9 a.m. ET to learn more about our Q1 2024 #earnings : merck.us/3rQwIL1 $MRK

Our Q1 2024 #earnings results are live. Check out our full $MRK financial summary and key highlights: merck.us/49MAtRO

Today, we announced the initiation of a new Phase 3 trial for one of our investigational #oncology pipeline candidates in certain patients with #lungcancer . Learn more: merck.us/3xqn8kH

We’re committed to advancing research in #ovariancancer . Today, we announced the initiation of a Phase 2/3 trial for the treatment of platinum-resistant ovarian cancer in collaboration with Daiichi Sankyo US. Learn more: merck.us/3PMqogA

Today, we announced an approval in the EU for our treatment for certain patients with #lungcancer . Learn more here: merck.us/3VBshR2

We’re proud to announce the #FDA approval of a new treatment option in #PulmonaryArterialHypertension . Learn more: merck.us/4a6SCuL

Learn more about our latest update in #lungcancer : merck.us/3Ptggcg

We’re pleased to share new data from multiple Phase 3 trials and a real-world evidence study in #pneumococcal disease. Learn more: merck.us/3Ptprth

We’re committed to supporting patients with #CervicalCancer . Read about our latest Phase 3 #oncology results here: merck.us/3ViKum0

Today, we announced the completion of our acquisition of Harpoon Therapeutics, expanding our diverse #oncology pipeline. Read our news here: merck.us/48ToKQS

Today, we announced a CHMP opinion recommending approval of our treatment for certain patients with #lungcancer . Learn more: merck.us/3uzKNOJ

We’re pleased to announce the #FDA has accepted our filing for the potential treatment of patients with advanced or recurrent #endometrial cancer. Learn more: merck.us/49DfG3q

Rob Davis, chairman and CEO, on our Q4 and full-year 2023 #earnings : merck.us/3HJtT2M $MRK

Join us today at 9 a.m. ET to learn more about our Q4 and full-year 2023 #earnings : merck.us/2Tv6Nnq $MRK

Our Q4 and full-year 2023 #earnings results are live. Check out our full $MRK financial summary and key highlights: merck.us/3SmwfcT

Today, we presented new late- breaking data from a Phase 3 trial of our #immunotherapy in earlier stages of #RenalCellCarcinoma . Learn more here: merck.us/47Uzvlz

Today, we presented new late-breaking data from a Phase 3 trial of our #immunotherapy in earlier stages of #BladderCancer . Read the full results here: merck.us/3ScOFNa

Today’s #FDA approval provides a new option for certain patients with #cervicalcancer . Read more here: merck.us/3TYa0wv